8-K/A: Onconetix Completes Acquisition of Proteomedix, Files Amended 8-K with Financials

Onconetix, Inc. has finalized its acquisition of Proteomedix AG, filing an amended 8-K to include the acquired company's financial statements and pro forma information.

Summary

• Onconetix, Inc. acquired Proteomedix AG through a share exchange transaction on December 15, 2023.
• This amendment to the original 8-K filing includes Proteomedix's audited financial statements for 2021 and 2022, and unaudited financials for the nine months ended September 30, 2023.
• Pro forma financial information is also provided, showing the combined financials as if the acquisition occurred on January 1, 2022.
• Onconetix issued 3,675,414 shares of common stock and 2,696,729 shares of Series B preferred stock to complete the acquisition.
• A private placement of $5.0 million in units was also completed with the PMX Investor, each unit including one share of common stock and a pre-funded warrant.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the acquisition and revenue growth are positive, the going concern uncertainty and accumulated losses temper the overall sentiment. The need for additional funding and the potential for integration challenges add to the uncertainty.

Positives

• The acquisition of Proteomedix expands Onconetix's portfolio and market presence.
• The inclusion of Proteomedix's financials provides transparency and a clearer picture of the combined entity's financial health.
• The private placement provides additional capital to support the combined operations.
• Proteomedix has shown significant revenue growth in the nine months ended September 30, 2023, with revenue of $2,092,761 compared to $128,773 in the same period of 2022.

Negatives

• Proteomedix has a history of losses and a significant accumulated deficit of approximately $27 million as of September 30, 2023.
• Proteomedix's financial statements include a going concern uncertainty due to recurring losses and a net capital deficiency.
• The pro forma financials do not include any anticipated synergies or cost savings from the acquisition.
• The pro forma financials do not include any adjustments related to the Subscription Agreement with the PMX Investor.

Risks

• Proteomedix's ability to continue as a going concern is dependent on additional funding from Onconetix.
• The final purchase price allocation may differ materially from the preliminary allocation.
• The combined entity may face integration challenges and costs.
• The pro forma financials do not reflect potential future operating efficiencies or cost savings.
• The company has a significant accumulated deficit and has a history of losses.

Future Outlook

Management intends to raise additional funds from its Parent to sustain operations until such time as revenues are sufficient to support the Company's operations.

Management Comments

• Management believes that the actions presently being taken to further implement its business plan and generate revenues provide the opportunity for the Company to continue as a going concern.
• Management intends to raise additional funds from its Parent to sustain operations until such time as revenues are sufficient to support the Company's operations.

Industry Context

The acquisition of Proteomedix, a company focused on prostate cancer diagnostics, aligns with the broader trend of consolidation and growth in the healthcare and biotechnology sectors. This move allows Onconetix to expand its offerings in the diagnostic space.

Comparison to Industry Standards

• Proteomedix's revenue growth in the nine months ended September 30, 2023, from $128,773 to $2,092,761, is a significant increase, suggesting strong market traction for its products.
• However, the company's history of losses and going concern uncertainty is not uncommon for early-stage biotech companies, which often require substantial investment in research and development before achieving profitability.
• Comparable companies in the diagnostic space, such as Exact Sciences and Guardant Health, have also experienced periods of significant losses while scaling their operations and commercializing their products.
• The pro forma financials show a combined entity with a significant accumulated deficit, which is typical for companies in the growth phase of the biotech industry.
• The acquisition of Proteomedix by Onconetix is similar to other strategic acquisitions in the biotech sector, where larger companies acquire smaller, innovative firms to expand their product portfolios and market reach.

Related Party Transactions

• Proteomedix has several borrowings from shareholders and members of its board of directors.
• Proteomedix paid approximately $319,000 and $289,000 in 2022 and $127,500 and $183,400 in 2023 to entities owned by a member of executive management and two members of the board of directors for professional services.

Stakeholder Impact

• Shareholders of Onconetix will see a dilution of their ownership due to the issuance of new shares for the acquisition.
• Employees of Proteomedix will become part of Onconetix, potentially impacting their roles and responsibilities.
• Customers of Proteomedix will now be served by the combined entity.
• Creditors of Proteomedix will have their debts converted into equity or assumed by Onconetix.

Next Steps

• Onconetix will file a resale registration statement with the SEC registering the resale of the Common Stock issuable pursuant to the Subscription Agreement and the Warrants.
• The final purchase price allocation will be determined when the Company has completed the detailed valuations and necessary calculations.
• The company will need to integrate the operations of Proteomedix into Onconetix.

Key Dates

Keywords

acquisition, Proteomedix, Onconetix, financial statements, pro forma, share exchange, biomarker, cancer diagnosis, private placement, convertible notes